Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Tarsus Pharmaceuticals, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 220
- +16 vs. Q2 2025
- Shares held
- 44.9M
- −766.1K (−1.7%) vs. Q2 2025
- Total value
- $2.67B
- +$818.1M (+44.2%) vs. Q2 2025
- New holders
- 37
- 66 more added
- Sold out
- 21
- 93 more reduced
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TARS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 256 | $2.98B |
| Q1 2026 | 253 | $3.17B |
| Q4 2025 | 246 | $3.61B |
| Q3 2025 | 220 | $2.67B |
| Q2 2025 | 205 | $1.87B |
| Q1 2025 | 195 | $2.26B |
| Q4 2024 | 195 | $2.23B |
| Q3 2024 | 162 | $1.43B |
| Q2 2024 | 148 | $1.09B |
| Q1 2024 | 157 | $1.43B |
| Q4 2023 | 116 | $652.0M |
| Q3 2023 | 105 | $529.4M |
| Q2 2023 | 92 | $387.3M |
| Q1 2023 | 74 | $252.1M |
| Q4 2022 | 69 | $301.0M |
| Q3 2022 | 75 | $350.8M |
| Q2 2022 | 73 | $291.7M |
| Q1 2022 | 51 | $222.2M |
| Q4 2021 | 43 | $294.2M |
| Q3 2021 | 44 | $277.4M |
| Q2 2021 | 44 | $378.5M |
| Q1 2021 | 41 | $410.4M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Tarsus Pharmaceuticals, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Clearbridge Investments, LLC | 566,978 | $33.7M | 0.03% | +122,476+27.6% | Added |
| D. E. Shaw & Co., Inc. | 598,307 | $35.6M | 0.03% | −124,876−17.3% | Reduced |
| Toronto Dominion Bank | 617,583 | $36.7M | 0.07% | −384,379−38.4% | Reduced |
| Macquarie Group Ltd | 833,437 | $49.5M | 0.06% | −115,413−12.2% | Reduced |
| State Street Corp | 936,162 | $55.6M | 0.00% | −44,706−4.6% | Reduced |
| Invesco Ltd. | 937,006 | $55.7M | 0.01% | +8,505+0.9% | Added |
| Geode Capital Management, LLC | 944,496 | $56.1M | 0.00% | +10,076+1.1% | Added |
| Lord, Abbett & Co. LLC | 985,629 | $58.6M | 0.17% | −9,796−1.0% | Reduced |
| Driehaus Capital Management LLC | 1,031,041 | $61.3M | 0.44% | +154,494+17.6% | Added |
| Frazier Life Sciences Management, L.P. | 1,167,527 | $69.4M | 2.08% | −230,000−16.5% | Reduced |
| Assenagon Asset Management S.A. | 1,247,954 | $74.2M | 0.11% | +250,367+25.1% | Added |
| Janus Henderson Group PLC | 1,438,999 | $85.6M | 0.04% | −367,948−20.4% | Reduced |
| Morgan Stanley | 1,912,402 | $113.7M | 0.01% | −143,316−7.0% | Reduced |
| Vanguard Group Inc | 2,272,090 | $135.0M | 0.00% | −25,264−1.1% | Reduced |
| Tang Capital Management LLC | 2,454,797 | $145.9M | 5.62% | 00.0% | Unchanged |
| Jennison Associates LLC | 2,604,580 | $154.8M | 0.09% | +136,582+5.5% | Added |
| Paradigm Biocapital Advisors LP | 2,665,698 | $158.4M | 4.69% | −310,401−10.4% | Reduced |
| Deep Track Capital, LP | 3,000,000 | $178.3M | 4.98% | +1,250,000+71.4% | Added |
| RTW Investments, LP | 3,177,436 | $188.8M | 2.33% | +65,756+2.1% | Added |
| BlackRock, Inc. | 3,779,621 | $224.6M | 0.00% | −12,564−0.3% | Reduced |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −543,000−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −138,019−100.0% | Sold out |
| Gilder Gagnon Howe & Co LLC | 0 | $0 | 0.00% | −77,164−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −52,334−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −36,354−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −32,411−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −24,774−100.0% | Sold out |
| Magnetar Financial LLC | 0 | $0 | 0.00% | −14,721−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −14,500−100.0% | Sold out |
| Warren Averett Asset Management, LLC | 0 | $0 | 0.00% | −13,197−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −11,905−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −10,729−100.0% | Sold out |
| Versor Investments LP | 0 | $0 | 0.00% | −9,492−100.0% | Sold out |
| Petrus Trust Company, LTA | 0 | $0 | 0.00% | −7,061−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −363−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −139−100.0% | Sold out |
| Accent Capital Management, LLC | 0 | $0 | 0.00% | −105−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −23−100.0% | Sold out |
| Twin Peaks Wealth Advisors, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Norges Bank | – | – | – | – | Not filed |